Exemestane vs Tamoxifen for hormones
Short answer: For hormones, more users report improvement with Tamoxifen — 98% of 49 reports, versus 67% of 3 for Exemestane.
Tamoxifen has 479 meta-analyses and 1,597 randomized trials on PubMed; the other has not been graded.
Based on 30 reports about Exemestane and 298 about Tamoxifen. Not medical advice.
| Exemestane Medication | Tamoxifen Medication | |
|---|---|---|
| Users say it helped | 18%helped5 reports · few reports | 64%helped75 reports · medium confidence |
| Verdict | Mixed | Mostly positive |
| Research | Not graded | AResearch: Strong |
| Meta-analyses / RCTs | — | 479 / 1,597 |
| Mainly used for | ||
| Hormones % reporting improvement | 67% (3) | 98% (49) |
| Libido % reporting improvement | — | 57% (7) |
| Energy % reporting improvement | — | 100% (5) |
| Common side effects | joint pain, hair loss, joint problems, fatigue | fatigue, depression, low libido, headache |
| Typical dose reported | Not listed | Not listed |
“I've had good results from their latest batches of aromasin, enclomiphene, and taladafil.”
5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death. ER status was the only recorded factor importantly predictive of the proportional reductions. Hence, the absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamoxifen.
Lancet, 2011 ↗“Dosage 5 mg starting at week 2. I upped the dose to 10 mg mid cycle due to slightly feeling suppressed.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate